A novel scoring system for TIGIT expression in classic Hodgkin lymphoma

Abstract Clinical use of immune-checkpoints inhibitors (anti PD-1/PD-L1) resulted very effective for the treatment of relapsed/refractory classic Hodgkin Lymphoma (CHL). Recently, T cell Ig and ITIM domains (TIGIT) has been recognized as an immune checkpoint receptor able to negatively regulate T ce...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ombretta Annibali, Antonella Bianchi, Alba Grifoni, Valeria Tomarchio, Mariantonietta Tafuri, Martina Verri, Giuseppe Avvisati, Anna Crescenzi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/de521050ce89405581166e0e1a9d158c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de521050ce89405581166e0e1a9d158c
record_format	dspace
spelling	oai:doaj.org-article:de521050ce89405581166e0e1a9d158c2021-12-02T14:23:14ZA novel scoring system for TIGIT expression in classic Hodgkin lymphoma10.1038/s41598-021-86655-82045-2322https://doaj.org/article/de521050ce89405581166e0e1a9d158c2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86655-8https://doaj.org/toc/2045-2322Abstract Clinical use of immune-checkpoints inhibitors (anti PD-1/PD-L1) resulted very effective for the treatment of relapsed/refractory classic Hodgkin Lymphoma (CHL). Recently, T cell Ig and ITIM domains (TIGIT) has been recognized as an immune checkpoint receptor able to negatively regulate T cell functions. Herein, we investigated the expression of TIGIT in CHL microenvironment in order to find a potential new target for inhibitor therapy. TIGIT, PD-1 and PD-L1 expression was evaluated in 34 consecutive patients with CHL. TIGIT expression in T lymphocytes surrounding Hodgkin Reed-Sternberg (HRS) cells was observed in 19/34 patients (56%), of which 11 (58%) had advanced stages. In 16/19 (84%) cases, TIGIT+ peritumoral T lymphocytes showed also PD-1 expression. All 15 TIGIT− patients had PD-L1 expression in HRS cells (100%) while among 19 TIGIT+ patients, 11 (58%) were PD-L1+ and 8 (42%) were PD-L1−. Using a new scoring system for TIGIT immunoreactivity, all TIGIT+ cases with higher score (4/19) were PD-L1−. Our results confirm co-expression of TIGIT and PD-1 in peritumoral T lymphocytes. Of relevance, we demonstrated a mutually exclusive expression of TIGIT and PD-L1 using new TIGIT scoring system able to identify this immunocheckpoints’ modulation. These results pave the way to new therapeutic strategies for relapsed/refractory CHL.Ombretta AnnibaliAntonella BianchiAlba GrifoniValeria TomarchioMariantonietta TafuriMartina VerriGiuseppe AvvisatiAnna CrescenziNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ombretta Annibali Antonella Bianchi Alba Grifoni Valeria Tomarchio Mariantonietta Tafuri Martina Verri Giuseppe Avvisati Anna Crescenzi A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
description	Abstract Clinical use of immune-checkpoints inhibitors (anti PD-1/PD-L1) resulted very effective for the treatment of relapsed/refractory classic Hodgkin Lymphoma (CHL). Recently, T cell Ig and ITIM domains (TIGIT) has been recognized as an immune checkpoint receptor able to negatively regulate T cell functions. Herein, we investigated the expression of TIGIT in CHL microenvironment in order to find a potential new target for inhibitor therapy. TIGIT, PD-1 and PD-L1 expression was evaluated in 34 consecutive patients with CHL. TIGIT expression in T lymphocytes surrounding Hodgkin Reed-Sternberg (HRS) cells was observed in 19/34 patients (56%), of which 11 (58%) had advanced stages. In 16/19 (84%) cases, TIGIT+ peritumoral T lymphocytes showed also PD-1 expression. All 15 TIGIT− patients had PD-L1 expression in HRS cells (100%) while among 19 TIGIT+ patients, 11 (58%) were PD-L1+ and 8 (42%) were PD-L1−. Using a new scoring system for TIGIT immunoreactivity, all TIGIT+ cases with higher score (4/19) were PD-L1−. Our results confirm co-expression of TIGIT and PD-1 in peritumoral T lymphocytes. Of relevance, we demonstrated a mutually exclusive expression of TIGIT and PD-L1 using new TIGIT scoring system able to identify this immunocheckpoints’ modulation. These results pave the way to new therapeutic strategies for relapsed/refractory CHL.
format	article
author	Ombretta Annibali Antonella Bianchi Alba Grifoni Valeria Tomarchio Mariantonietta Tafuri Martina Verri Giuseppe Avvisati Anna Crescenzi
author_facet	Ombretta Annibali Antonella Bianchi Alba Grifoni Valeria Tomarchio Mariantonietta Tafuri Martina Verri Giuseppe Avvisati Anna Crescenzi
author_sort	Ombretta Annibali
title	A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
title_short	A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
title_full	A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
title_fullStr	A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
title_full_unstemmed	A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
title_sort	novel scoring system for tigit expression in classic hodgkin lymphoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/de521050ce89405581166e0e1a9d158c
work_keys_str_mv	AT ombrettaannibali anovelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT antonellabianchi anovelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT albagrifoni anovelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT valeriatomarchio anovelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT mariantoniettatafuri anovelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT martinaverri anovelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT giuseppeavvisati anovelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT annacrescenzi anovelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT ombrettaannibali novelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT antonellabianchi novelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT albagrifoni novelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT valeriatomarchio novelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT mariantoniettatafuri novelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT martinaverri novelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT giuseppeavvisati novelscoringsystemfortigitexpressioninclassichodgkinlymphoma AT annacrescenzi novelscoringsystemfortigitexpressioninclassichodgkinlymphoma
_version_	1718391457474150400

A novel scoring system for TIGIT expression in classic Hodgkin lymphoma

Ejemplares similares